View source for 17930234. COMPOSITIONS, METHODS, MODELS AND USES FOR SIMIAN VARICELLA VIRUS (SVV) CHIMERIC CONSTRUCTS IN HUMAN HEALTH CONDITIONS simplified abstract (THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE)

=COMPOSITIONS, METHODS, MODELS AND USES FOR SIMIAN VARICELLA VIRUS (SVV) CHIMERIC CONSTRUCTS IN HUMAN HEALTH CONDITIONS=


==Organization Name==

[[:Category:THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE|THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE]]


[[Category:THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE]]

==Inventor(s)==

[[:Category:Ravi Mahalingam of Aurora CO (US)|Ravi Mahalingam of Aurora CO (US)]][[Category:Ravi Mahalingam of Aurora CO (US)]]

[[:Category:Vicki L. Traina-dorge of Covington LA (US)|Vicki L. Traina-dorge of Covington LA (US)]][[Category:Vicki L. Traina-dorge of Covington LA (US)]]

[[:Category:Hua Zhu of Plainsboro NJ (US)|Hua Zhu of Plainsboro NJ (US)]][[Category:Hua Zhu of Plainsboro NJ (US)]]

==COMPOSITIONS, METHODS, MODELS AND USES FOR SIMIAN VARICELLA VIRUS (SVV) CHIMERIC CONSTRUCTS IN HUMAN HEALTH CONDITIONS - A simplified explanation of the abstract==


This abstract first appeared for US patent application 17930234 titled 'COMPOSITIONS, METHODS, MODELS AND USES FOR SIMIAN VARICELLA VIRUS (SVV) CHIMERIC CONSTRUCTS IN HUMAN HEALTH CONDITIONS

==Simplified Explanation==

Embodiments of the instantly claimed inventions include chimeric viral constructs, non-human primate models, in vivo screening systems for antiviral agents, gene therapy delivery systems, and methods of making and using the same.

* Chimeric viral constructs: These constructs consist of a non-human primate infecting virus nucleic acid sequence and an exclusively human pathogenic virus nucleic acid sequence for creating a non-human primate model.
* In vivo screening systems for antiviral agents: These systems are designed to test the effectiveness of antiviral agents.
* Gene therapy delivery systems: These systems can deliver a vector containing or associated with an agent to a human subject for treating conditions of the skin and neuronal ganglia.

== Potential Applications ==
The technology described in this patent application could be applied in the development of new antiviral treatments, gene therapy for skin and neuronal conditions, and the creation of non-human primate models for research purposes.

== Problems Solved ==
This technology addresses the need for more effective antiviral agents, improved gene therapy delivery systems, and better research models for studying human pathogenic viruses.

== Benefits ==
The benefits of this technology include potential advancements in antiviral treatments, gene therapy for various conditions, and a better understanding of viral infections through non-human primate models.

== Potential Commercial Applications ==
Potential commercial applications of this technology could include the development of new antiviral drugs, gene therapy products for skin and neuronal conditions, and services related to non-human primate research models.

== Possible Prior Art ==
One possible prior art in this field could be existing gene therapy delivery systems and antiviral screening methods that have been previously patented or published in scientific literature.

=== Unanswered Questions ===

=== How does this technology compare to existing antiviral treatments and gene therapy delivery systems in terms of efficacy and safety? ===
The article does not provide a direct comparison between this technology and existing treatments or delivery systems. Further research and clinical trials would be needed to determine the effectiveness and safety of these new innovations.

=== What are the potential ethical considerations surrounding the use of non-human primate models in research for human pathogenic viruses? ===
The article does not address the ethical implications of using non-human primate models in research. Ethical discussions and guidelines may need to be considered before implementing this technology in research settings.


==Original Abstract Submitted==

Embodiments of the instantly claimed inventions include, but are not limited to, chimeric viral constructs, non-human primate models, in vivo screening systems for antiviral agents, gene therapy delivery systems, and methods of making and using the same. In some embodiments, chimeric viral constructs include a non-human primate infecting virus nucleic acid sequence and a exclusively human pathogenic virus nucleic acid sequence for use in creating a non-human primate model and uses thereof. In other embodiments, systems for testing antiviral agents are disclosed. In other embodiments, gene therapy delivery systems disclosed herein can be used to deliver a vector containing or associated with an agent to a human subject for treating conditions of the skin and neuronal ganglia in the subject.



[[Category:A61K49/00]]
[[Category:C07K14/005]]
[[Category:C12N7/00]]